Victoza tops lixisenatide in head-to-head trial

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said Victoza liraglutide was superior to lixisenatide from Zealand Pharma A/S (CSE:ZEAL) and Sanofi (Euronext:SAN; NYSE:SNY) in the Phase IV LIRA-LIXI trial to treat Type II diabetes, leading to significantly greater reduction in HbA1C after 26 weeks (p<0.0001).

Victoza, a long-acting analog of glucagon-like peptide-1 (GLP-1), is approved in the U.S. and EU to treat Type II diabetes. Sanofi markets lixisenatide, a GLP-1 receptor ( GLP-1R; GLP1R) agonist, in the EU as Lyxumia; it is under FDA review. ...